Nifty
Sensex
:
:
23250.10
76295.36
-82.25 (-0.35%)
-322.08 (-0.42%)

Pharmaceuticals & Drugs - Global

Rating :
N/A

BSE: 524404 | NSE: MARKSANS

269.26
06-Feb-2025
  • Open
  • High
  • Low
  • Previous Close
  •  269.90
  •  276.15
  •  264.54
  •  269.96
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1343467
  •  3619.69
  •  358.70
  •  130.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 10,560.98
  • 28.67
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 9,928.38
  • 0.26%
  • 4.43

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 43.87%
  • 1.25%
  • 26.24%
  • FII
  • DII
  • Others
  • 21.95%
  • 3.15%
  • 3.54%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.58
  • 13.93
  • 13.46

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.06
  • 18.99
  • 12.11

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.11
  • 21.80
  • 19.34

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.52
  • 14.49
  • 18.62

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.84
  • 3.05
  • 3.22

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 12.08
  • 10.34
  • 12.03

Earnings Forecasts:

Description
2024
2025
2026
2027
Adj EPS
6.92
8.68
11.02
13.2
P/E Ratio
49.93
39.81
31.36
26.17
Revenue
2177
2610
3091
3584
EBITDA
459
563
692
821
Net Income
314
387
499
597
ROA
12.9
13
13.7
P/B Ratio
7.58
6.4
5.37
4.5
ROE
16.47
16.68
18.02
18.9
FCFF
47.26
202.45
345.95
435.4
FCFF Yield
0.32
1.36
2.33
2.93

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Net Sales
681.85
586.13
16.33%
641.92
531.24
20.83%
590.62
500.03
18.12%
560.01
485.98
15.23%
Expenses
543.08
453.11
19.86%
506.24
417.29
21.32%
462.18
398.07
16.11%
450.37
376.43
19.64%
EBITDA
138.76
133.02
4.32%
135.68
113.95
19.07%
128.44
101.97
25.96%
109.64
109.55
0.08%
EBIDTM
20.35%
22.70%
21.14%
21.45%
21.75%
20.39%
19.58%
22.54%
Other Income
27.85
4.80
480.21%
11.06
19.00
-41.79%
14.95
10.10
48.02%
16.53
11.01
50.14%
Interest
2.67
3.16
-15.51%
2.63
1.63
61.35%
2.92
1.58
84.81%
4.84
2.44
98.36%
Depreciation
20.69
22.00
-5.95%
19.51
17.55
11.17%
20.44
13.66
49.63%
21.05
13.94
51.00%
PBT
143.26
112.66
27.16%
124.60
113.77
9.52%
120.02
96.83
23.95%
100.28
104.17
-3.73%
Tax
38.19
29.69
28.63%
26.84
29.92
-10.29%
30.95
26.39
17.28%
22.63
21.46
5.45%
PAT
105.07
82.97
26.64%
97.76
83.85
16.59%
89.07
70.44
26.45%
77.64
82.71
-6.13%
PATM
15.41%
14.15%
15.23%
15.78%
15.08%
14.09%
13.86%
17.02%
EPS
2.31
1.84
25.54%
2.13
1.84
15.76%
1.96
1.52
28.95%
1.73
1.81
-4.42%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
2,474.40
2,177.41
1,852.14
1,490.84
1,376.18
1,134.21
1,000.07
912.69
767.16
893.33
796.69
Net Sales Growth
17.64%
17.56%
24.23%
8.33%
21.33%
13.41%
9.57%
18.97%
-14.12%
12.13%
 
Cost Of Goods Sold
1,088.34
1,038.12
921.36
716.81
595.05
567.83
498.01
523.13
458.74
509.69
445.44
Gross Profit
1,386.06
1,139.29
930.78
774.02
781.13
566.38
502.07
389.57
308.42
383.63
351.25
GP Margin
56.02%
52.32%
50.25%
51.92%
56.76%
49.94%
50.20%
42.68%
40.20%
42.94%
44.09%
Total Expenditure
1,961.87
1,718.83
1,512.82
1,231.96
1,036.58
941.96
867.92
834.31
734.24
760.91
620.86
Power & Fuel Cost
-
36.94
24.50
18.59
16.42
14.38
14.34
11.83
13.27
12.58
9.72
% Of Sales
-
1.70%
1.32%
1.25%
1.19%
1.27%
1.43%
1.30%
1.73%
1.41%
1.22%
Employee Cost
-
293.64
239.37
220.30
197.32
168.42
159.07
147.75
149.70
122.42
72.61
% Of Sales
-
13.49%
12.92%
14.78%
14.34%
14.85%
15.91%
16.19%
19.51%
13.70%
9.11%
Manufacturing Exp.
-
136.67
96.47
12.73
127.47
113.32
77.14
59.90
47.34
50.44
37.59
% Of Sales
-
6.28%
5.21%
0.85%
9.26%
9.99%
7.71%
6.56%
6.17%
5.65%
4.72%
General & Admin Exp.
-
59.73
52.79
37.74
50.67
45.52
51.03
42.51
37.52
36.01
15.35
% Of Sales
-
2.74%
2.85%
2.53%
3.68%
4.01%
5.10%
4.66%
4.89%
4.03%
1.93%
Selling & Distn. Exp.
-
127.31
133.19
119.05
33.54
32.15
68.36
49.14
27.66
29.77
34.47
% Of Sales
-
5.85%
7.19%
7.99%
2.44%
2.83%
6.84%
5.38%
3.61%
3.33%
4.33%
Miscellaneous Exp.
-
26.42
45.14
106.73
16.10
0.34
-0.01
0.05
0.00
0.00
34.47
% Of Sales
-
1.21%
2.44%
7.16%
1.17%
0.03%
0.00%
0.01%
0%
0%
0.71%
EBITDA
512.52
458.58
339.32
258.88
339.60
192.25
132.15
78.38
32.92
132.42
175.83
EBITDA Margin
20.71%
21.06%
18.32%
17.36%
24.68%
16.95%
13.21%
8.59%
4.29%
14.82%
22.07%
Other Income
70.39
50.42
59.31
41.85
6.69
0.33
4.62
8.47
18.85
12.72
12.23
Interest
13.06
11.20
9.13
8.45
7.99
8.75
9.66
10.22
6.78
10.16
16.05
Depreciation
81.69
74.27
51.85
44.78
36.15
26.66
22.80
26.84
30.09
28.13
16.13
PBT
488.16
423.53
337.65
247.51
302.16
157.17
104.31
49.80
14.90
106.85
155.88
Tax
118.61
108.63
72.33
60.70
63.63
36.42
23.87
14.00
3.56
24.11
43.92
Tax Rate
24.30%
25.65%
21.42%
24.52%
21.06%
23.17%
22.88%
28.11%
23.89%
22.56%
28.18%
PAT
369.54
313.69
266.31
184.56
235.94
117.02
76.46
32.94
8.83
78.51
109.39
PAT before Minority Interest
368.33
314.89
265.32
186.81
238.54
120.75
80.44
35.80
11.33
82.74
111.96
Minority Interest
-1.21
-1.20
0.99
-2.25
-2.60
-3.73
-3.98
-2.86
-2.50
-4.23
-2.57
PAT Margin
14.93%
14.41%
14.38%
12.38%
17.14%
10.32%
7.65%
3.61%
1.15%
8.79%
13.73%
PAT Growth
15.49%
17.79%
44.29%
-21.78%
101.62%
53.05%
132.12%
273.05%
-88.75%
-28.23%
 
EPS
8.15
6.92
5.88
4.07
5.21
2.58
1.69
0.73
0.19
1.73
2.41

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
2,065.05
1,745.16
1,202.27
886.50
636.01
542.48
470.86
433.43
454.32
379.76
Share Capital
45.32
45.32
40.93
40.93
40.93
40.93
40.93
40.93
53.43
53.43
Total Reserves
2,019.74
1,699.85
1,068.24
845.56
595.08
501.55
429.93
392.50
400.89
326.33
Non-Current Liabilities
205.20
84.33
57.05
23.70
24.15
17.14
15.64
16.07
-1.91
1.46
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Provisions
4.56
3.25
1.86
2.11
1.47
1.36
1.08
0.96
0.00
0.00
Current Liabilities
389.85
340.99
380.08
298.97
228.75
232.62
234.68
296.06
259.43
286.24
Trade Payables
268.28
230.60
200.08
168.66
110.33
106.07
77.83
161.78
118.98
107.02
Other Current Liabilities
70.62
42.20
96.80
79.69
58.86
20.90
10.08
0.71
0.68
39.88
Short Term Borrowings
29.09
41.59
41.29
18.74
18.84
99.91
117.41
109.71
87.89
82.19
Short Term Provisions
21.86
26.60
41.92
31.88
40.72
5.74
29.36
23.85
51.88
57.15
Total Liabilities
2,680.95
2,190.39
1,660.10
1,228.03
902.02
802.46
730.73
751.81
720.20
675.56
Net Block
775.94
486.31
428.31
309.36
302.72
269.73
279.38
266.98
269.65
165.90
Gross Block
1,193.49
828.26
726.26
551.92
565.39
506.26
495.35
456.49
429.47
297.78
Accumulated Depreciation
417.55
341.95
297.96
242.56
262.67
236.54
215.97
189.52
159.82
131.89
Non Current Assets
818.46
515.09
435.04
325.20
308.45
271.02
280.19
267.92
280.06
166.72
Capital Work in Progress
9.42
9.87
2.57
11.68
0.00
0.00
0.00
0.36
0.00
0.00
Non Current Investment
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Loans & Adv.
32.94
18.91
4.16
4.16
5.73
1.29
0.82
0.59
10.41
0.83
Other Non Current Assets
0.17
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
1,862.49
1,675.30
1,225.07
902.82
593.59
531.44
450.54
483.88
440.15
508.83
Current Investments
26.99
0.54
0.44
0.26
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
617.94
484.74
424.44
404.32
241.84
293.25
218.12
190.09
167.79
130.11
Sundry Debtors
453.18
416.85
394.78
271.95
243.35
176.60
176.91
247.58
217.29
183.45
Cash & Bank
673.58
714.96
349.26
212.18
93.73
33.54
39.88
25.16
35.30
185.27
Other Current Assets
90.80
22.74
24.36
14.11
14.66
28.06
15.63
21.05
19.76
10.01
Short Term Loans & Adv.
59.82
35.48
31.79
0.00
3.40
0.00
0.00
20.96
19.76
10.01
Net Current Assets
1,472.64
1,334.31
844.98
603.85
364.83
298.82
215.86
187.82
180.71
222.60
Total Assets
2,680.95
2,190.39
1,660.11
1,228.02
902.04
802.46
730.73
751.80
720.21
675.55

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
230.41
237.41
99.26
178.59
233.33
27.40
50.09
14.06
30.80
154.51
PBT
423.53
337.65
247.51
302.16
157.17
104.31
49.80
14.90
106.85
109.40
Adjustment
55.42
74.24
35.31
56.57
42.04
31.88
43.99
26.58
39.63
24.26
Changes in Working Capital
-126.19
-111.47
-110.70
-131.61
59.12
-81.79
-36.23
-6.04
-88.14
20.27
Cash after chg. in Working capital
352.76
300.43
172.12
227.12
258.33
54.40
57.56
35.44
58.34
153.94
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-122.35
-63.01
-72.86
-48.53
-25.00
-27.00
-7.46
-21.37
-27.54
-0.89
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-140.84
-259.21
-84.39
-44.85
-59.58
-13.48
-38.81
-20.73
-123.01
-33.19
Net Fixed Assets
-149.99
-21.45
-24.09
-28.48
-23.87
-23.07
-5.86
-11.49
-22.01
-32.23
Net Investments
-26.45
-29.78
-0.18
-0.26
0.00
0.00
-1.78
-2.85
-163.82
0.00
Others
35.60
-207.98
-60.12
-16.11
-35.71
9.59
-31.17
-6.39
62.82
-0.96
Cash from Financing Activity
-68.73
197.83
79.51
-15.29
-113.55
-20.78
3.38
-3.47
-57.75
16.99
Net Cash Inflow / Outflow
20.84
176.03
94.38
118.46
60.19
-6.86
14.67
-10.14
-149.96
138.32
Opening Cash & Equivalents
382.44
206.41
112.03
93.73
33.54
39.72
25.05
35.30
185.27
46.95
Closing Cash & Equivalent
403.28
382.44
206.41
212.18
93.73
32.85
39.72
25.16
35.30
185.27

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
45.57
38.51
27.10
21.66
15.54
13.25
11.50
10.59
10.79
8.97
ROA
12.93%
13.78%
12.94%
22.40%
14.17%
10.49%
4.83%
1.54%
11.86%
19.21%
ROE
16.53%
18.59%
18.72%
31.33%
20.49%
15.88%
7.92%
2.59%
20.45%
45.15%
ROCE
22.40%
22.89%
23.82%
39.76%
25.57%
18.51%
10.60%
3.99%
23.16%
44.64%
Fixed Asset Turnover
2.26
2.62
2.42
2.49
2.12
2.00
1.92
1.73
2.46
2.85
Receivable days
69.35
72.63
78.56
67.57
67.57
64.51
84.88
110.59
81.87
80.88
Inventory Days
87.89
81.36
97.65
84.73
86.10
93.32
81.63
85.14
60.86
53.30
Payable days
87.70
85.31
93.88
85.57
45.09
38.48
55.10
65.56
54.58
56.06
Cash Conversion Cycle
69.54
68.67
82.33
66.73
108.58
119.35
111.40
130.17
88.15
78.13
Total Debt/Equity
0.01
0.02
0.04
0.02
0.03
0.18
0.25
0.25
0.19
0.23
Interest Cover
38.80
37.99
30.31
38.84
18.97
11.80
5.87
3.20
11.52
10.72

News Update:


  • Marksans Pharma’s Goa facility gets Australian TGA’s nod to manufacture pharmaceutical formulations
    20th Mar 2025, 14:51 PM

    The products will be manufactured at the facility in Goa, India and marketed & distributed in Australian markets through the company’s subsidiary

    Read More
  • Marksans Pharma’s arm receives marketing authorization for Baclofen
    19th Mar 2025, 16:40 PM

    Relonchem has received Marketing Authorization from UK MHRA

    Read More
  • Marksans Pharma’s arm receives marketing authorization
    25th Feb 2025, 13:00 PM

    Relonchem has received marketing authorization for the product Ibuprofen and Paracetamol

    Read More
  • Marksans Pharma reports 27% rise in Q3 consolidated net profit
    12th Feb 2025, 11:10 AM

    Total consolidated income of the company increased by 20.10% at Rs 709.70 crore for Q3FY25

    Read More
  • Marksans Pharma - Quarterly Results
    11th Feb 2025, 20:53 PM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.